Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 31st total of 6,100 shares. Based on an average daily volume of 10,700 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.2% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Trading Up 1.9 %

NYSEAMERICAN:ARMP traded up $0.04 during trading hours on Wednesday, reaching $2.12. 792 shares of the company traded hands, compared to its average volume of 10,719. The stock has a market capitalization of $76.70 million, a price-to-earnings ratio of -1.29 and a beta of 0.85. Armata Pharmaceuticals has a 1 year low of $1.80 and a 1 year high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.